Nimbus Therapeutics is advancing NDI-101150, an orally bioavailable Hematopoietic Progenitor Kinase 1 (HPK1) inhibitor, through Phase I/II clinical trials for the treatment of advanced solid tumors. The development of this drug is rooted in HPK1's critical role in modulating immune responses, particularly within T-cells, B-cells, and dendritic cells.
HPK1 as an Immuno-Oncology Target
HPK1 is a kinase that regulates signaling pathways in immune cells, influencing their activation and function. Its role in suppressing T-cell activity makes it an attractive target for immuno-oncology. By inhibiting HPK1, the immune system's ability to recognize and attack cancer cells can be enhanced.
Preclinical Evidence
Preclinical studies involving HPK1-deficient mice have demonstrated enhanced anti-tumor T-cell responses and a marked resistance to tumor growth. These findings provided a strong rationale for the development of HPK1 inhibitors as potential cancer therapeutics.
Clinical Development and ACS Presentation
The discovery of NDI-101150 and interim results from ongoing clinical trials were presented by Nimbus Therapeutics at the ACS Fall 2024 First-Time Disclosures session. This highlights the company's commitment to developing novel therapies in immuno-oncology. Further details regarding the clinical trial design, patient population, and efficacy data are anticipated as the trial progresses.
